Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)
Clinical trial NCT02626000 · COMPLETED
Trial details
- NCT number
- NCT02626000
- Sponsor
- Amgen
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-04-06
- Primary completion
- 2017-11-02
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.